116 related articles for article (PubMed ID: 35143825)
1. Hydrazonoyl chlorides possess promising antitumor properties.
El Gendy MAM; Hassanein H; Saleh FM; Karimi-Busheri F; Fanta M; Yang X; Tawfik D; Morsy S; Fahmy M; Hemid M; Abdel Azeiz M; Fared A; Weinfeld M
Life Sci; 2022 Apr; 295():120380. PubMed ID: 35143825
[TBL] [Abstract][Full Text] [Related]
2. Cryptolepine Analog Exhibits Antitumor Activity against Ehrlich Ascites Carcinoma Cells in Mice
El-Aarag B; Shalaan ES; Ahmed AAS; El Sayed IET; Ibrahim WM
Anticancer Agents Med Chem; 2024; 24(6):436-442. PubMed ID: 38305388
[TBL] [Abstract][Full Text] [Related]
3. Biological Activity, Apoptotic Induction and Cell Cycle Arrest of New Hydrazonoyl Halides Derivatives.
Mohamed MF; Hassaneen HM; Elzayat EM; El-Hallouty SM; El-Manawaty M; Saleh FM; Mohamed Y; El-Zohiry D; Fahmy G; Abdelaal N; Hassanin N; Hossam N
Anticancer Agents Med Chem; 2019; 19(9):1141-1149. PubMed ID: 30843494
[TBL] [Abstract][Full Text] [Related]
4. Deoxyshikonin isolated from
Zhu Y; Zhong Y; Long X; Zhu Z; Zhou Y; Ye H; Zeng X; Zheng X
Pharm Biol; 2019 Dec; 57(1):412-423. PubMed ID: 31230505
[No Abstract] [Full Text] [Related]
5. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
Herzog A; Bian Y; Vander Broek R; Hall B; Coupar J; Cheng H; Sowers AL; Cook JD; Mitchell JB; Chen Z; Kulkarni AB; Van Waes C
Clin Cancer Res; 2013 Jul; 19(14):3808-19. PubMed ID: 23640975
[TBL] [Abstract][Full Text] [Related]
6. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
8. Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN.
Deng W; Han W; Fan T; Wang X; Cheng Z; Wan B; Chen J
Biomed Pharmacother; 2018 Nov; 107():1505-1513. PubMed ID: 30257368
[TBL] [Abstract][Full Text] [Related]
9. Zeylenone, a naturally occurring cyclohexene oxide, inhibits proliferation and induces apoptosis in cervical carcinoma cells via PI3K/AKT/mTOR and MAPK/ERK pathways.
Zhang L; Huo X; Liao Y; Yang F; Gao L; Cao L
Sci Rep; 2017 May; 7(1):1669. PubMed ID: 28490807
[TBL] [Abstract][Full Text] [Related]
10. Autophagy inhibitor potentiates the antitumor efficacy of apatinib in uterine sarcoma by stimulating PI3K/Akt/mTOR pathway.
Chen S; Yao L
Cancer Chemother Pharmacol; 2021 Aug; 88(2):323-334. PubMed ID: 33978839
[TBL] [Abstract][Full Text] [Related]
11. Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K/Akt/mTOR signaling pathway.
Guo Y; Chang H; Li J; Xu XY; Shen L; Yu ZB; Liu WC
Apoptosis; 2015 Aug; 20(8):1109-21. PubMed ID: 26002438
[TBL] [Abstract][Full Text] [Related]
12. Oxymatrine synergistically enhances antitumor activity of oxaliplatin in colon carcinoma through PI3K/AKT/mTOR pathway.
Liu Y; Bi T; Wang Z; Wu G; Qian L; Gao Q; Shen G
Apoptosis; 2016 Dec; 21(12):1398-1407. PubMed ID: 27671687
[TBL] [Abstract][Full Text] [Related]
13. Small molecule schweinfurthins selectively inhibit cancer cell proliferation and mTOR/AKT signaling by interfering with trans-Golgi-network trafficking.
Bao X; Zheng W; Hata Sugi N; Agarwala KL; Xu Q; Wang Z; Tendyke K; Lee W; Parent L; Li W; Cheng H; Shen Y; Taylor N; Dezso Z; Du H; Kotake Y; Zhao N; Wang J; Postema M; Woodall-Jappe M; Takase Y; Uenaka T; Kingston DG; Nomoto K
Cancer Biol Ther; 2015; 16(4):589-601. PubMed ID: 25729885
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor efficacy of phellamurin in osteosarcoma cells: Involvement of the PI3K/AKT/mTOR pathway.
Zhang H; Jiang H; Zhang H; Liu J; Hu X; Chen L
Eur J Pharmacol; 2019 Sep; 858():172477. PubMed ID: 31228450
[TBL] [Abstract][Full Text] [Related]
15. Jolkinolide B induces apoptosis in MCF-7 cells through inhibition of the PI3K/Akt/mTOR signaling pathway.
Xu HY; Chen ZW; Hou JC; Du FX; Liu JC
Oncol Rep; 2013 Jan; 29(1):212-8. PubMed ID: 23129237
[TBL] [Abstract][Full Text] [Related]
16. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
[TBL] [Abstract][Full Text] [Related]
17. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis induced by the methanol extract of Salvia miltiorrhiza Bunge in non-small cell lung cancer through PTEN-mediated inhibition of PI3K/Akt pathway.
Ye YT; Zhong W; Sun P; Wang D; Wang C; Hu LM; Qian JQ
J Ethnopharmacol; 2017 Mar; 200():107-116. PubMed ID: 28088493
[TBL] [Abstract][Full Text] [Related]
19. Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway.
Zhou J; Jiang YY; Chen H; Wu YC; Zhang L
Cell Prolif; 2020 Feb; 53(2):e12739. PubMed ID: 31820522
[TBL] [Abstract][Full Text] [Related]
20. PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.
Seront E; Pinto A; Bouzin C; Bertrand L; Machiels JP; Feron O
Br J Cancer; 2013 Sep; 109(6):1586-92. PubMed ID: 23989949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
